News and Events

News

All categories

Earnings

Press Release

All years

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed to Present at the Jefferies 2018 London Healthcare Conference

November 8, 2018

Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress

November 7, 2018

Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting

November 1, 2018

Affimed Announces Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

October 31, 2018

Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold

October 8, 2018

Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference

August 30, 2018

Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

August 27, 2018

Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress

August 8, 2018

Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call

August 3, 2018

Affimed Announces Updated Data of AFM13 in Combination with Keytruda^® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA

June 15, 2018

Events

All

Scientific

Investors

18Oct

Innate Killer Summit Europe

October 18 - 20, 2022 (London, UK)

02Nov

Onco Cell Therapy Summit

November 2 - 3, 2022 (Amsterdam, NL)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed to Present at the Jefferies 2018 London Healthcare Conference

Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress

Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology Annual Meeting

Affimed Announces Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018

Affimed Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold

Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference

Affimed Announces Collaboration with Genentech to Develop Novel NK Cell Engager-based Immunotherapeutics for Multiple Cancer Targets

Affimed Reports Financial Results for Second Quarter 2018 and Operational Progress

Affimed Announces Second Quarter 2018 Financial Results and Corporate Update Conference Call

Affimed Announces Updated Data of AFM13 in Combination with Keytruda^® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA

Events

Innate Killer Summit Europe

Onco Cell Therapy Summit